Cargando…

Endocrine Therapy for Breast Cancer: A Model of Hormonal Manipulation

Oestrogen receptor (ER) is the driving transcription factor in 70% of breast cancer. Endocrine therapies targeting the ER represent one of the most successful anticancer strategies to date. In the clinic, novel targeted agents are now being exploited in combination with established endocrine therapi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Johnston, Simon J., Cheung, Kwok-Leung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360014/ https://www.ncbi.nlm.nih.gov/pubmed/32700026 http://dx.doi.org/10.1007/s40487-018-0062-x

Ejemplares similares

Endocrinology and hormone therapy in breast cancer: Endocrine therapy in premenopausal women
por: Pritchard, Kathleen
Publicado: (2005)

In vitro breast cancer models for studying mechanisms of resistance to endocrine therapy
por: Cheng, Gary J., et al.
Publicado: (2022)

Clinical relevance of "withdrawal therapy" as a form of hormonal manipulation for breast cancer
por: Agrawal, Amit, et al.
Publicado: (2011)

Endocrine therapy combined with targeted therapy in hormone receptor-positive metastatic breast cancer
por: Bian, Li, et al.
Publicado: (2020)

Endocrine manipulations in cancer prostate: A review
por: Rajput, Rajesh, et al.
Publicado: (2012)

The role of hormonal factors and endocrine therapy in ovarian cancer
por: Serkies, Krystyna, et al.
Publicado: (2013)

The Effects Induced by Spinal Manipulative Therapy on the Immune and Endocrine Systems
por: Colombi, Andrea, et al.
Publicado: (2019)

Invasive Lobular Breast Cancer as a Distinct Disease: Implications for Therapeutic Strategy
por: Luveta, Jocelyn, et al.
Publicado: (2019)

Manipulating Protein Acetylation in Breast Cancer: A Promising Approach in Combination with Hormonal Therapies?
por: Linares, Aurélien, et al.
Publicado: (2011)

Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
por: D’Souza, Anishka, et al.
Publicado: (2018)

Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98
por: Koeberle, Dieter, et al.
Publicado: (2007)

Hormonal treatment combined with targeted therapies in endocrine-responsive and HER2-positive metastatic breast cancer
por: Montagna, Emilia, et al.
Publicado: (2019)

Endocrinology and hormone therapy in breast cancer: New insight into estrogen receptor-α function and its implication for endocrine therapy resistance in breast cancer
por: Schiff, Rachel, et al.
Publicado: (2005)

Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG)
por: Abraham, Jame, et al.
Publicado: (2018)

Status of adjuvant endocrine therapy for breast cancer
por: Schiavon, Gaia, et al.
Publicado: (2014)

The immunomodulatory effects of endocrine therapy in breast cancer
por: Huang, Huanhuan, et al.
Publicado: (2021)

Updates in endocrine therapy for metastatic breast cancer
por: Manohar, Poorni M., et al.
Publicado: (2022)

Safety of adjuvant endocrine therapies in hormone receptor–positive early breast cancer
por: Sehdev, S., et al.
Publicado: (2009)

Endocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to Therapy
por: Rani, Aradhana, et al.
Publicado: (2019)

Appraising Adjuvant Endocrine Therapy in Hormone Receptor Positive HER2-Negative Breast Cancer—A Literature Review
por: Mata, Danilo Giffoni de Mello Morais, et al.
Publicado: (2022)

Novel Strategies to Improve the Endocrine Therapy of Breast Cancer
por: Castrellon, Aurelio Bartolome
Publicado: (2017)

The role of the tumor microenvironment in endocrine therapy resistance in hormone receptor-positive breast cancer
por: Yuan, Jie, et al.
Publicado: (2023)

Impact of Chemical Endocrine Disruptors and Hormone Modulators on the Endocrine System
por: Guarnotta, Valentina, et al.
Publicado: (2022)

An updated review on the efficacy of adjuvant endocrine therapies in hormone receptor– positive early breast cancer
por: Verma, S., et al.
Publicado: (2009)

Endocrinology and hormone therapy in breast cancer: Selective oestrogen receptor modulators and downregulators for breast cancer – have they lost their way?
por: Johnston, Stephen RD
Publicado: (2005)

Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer
por: Forward, D P, et al.
Publicado: (2004)

Observational cohort study to determine the degree and causes of variation in the rate of surgery or primary endocrine therapy in older women with operable breast cancer
por: Morgan, Jenna L., et al.
Publicado: (2021)

Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer
por: Alataki, Anastasia, et al.
Publicado: (2022)

Metastatic breast cancer: Endocrine therapy landscape reshaped
por: Salkeni, Mohamad Adham, et al.
Publicado: (2017)

Response to endocrine manipulation and oestrogen receptor concentration in large operable primary breast cancer.
por: Anderson, E. D., et al.
Publicado: (1989)

Pharmacological sex hormone manipulation as a risk model for depression
por: Frokjaer, Vibe G.
Publicado: (2020)

Hormone Production in Endocrine Tumours
por: Abelson, Denis
Publicado: (1958)

Neoadjuvant Endocrine Therapy in Breast Cancer Management: State of the Art
por: Lerebours, Florence, et al.
Publicado: (2021)

The Present and Future of Neoadjuvant Endocrine Therapy for Breast Cancer Treatment
por: Martí, Covadonga, et al.
Publicado: (2021)

RETRACTION: Challenges of Combined Everolimus/Endocrine Therapy in Hormone Receptor-Positive Metastatic Breast Cancer
por: Porta, Camillo
Publicado: (2014)

The Role of Ki67 in Evaluating Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer
por: Zhang, Ailin, et al.
Publicado: (2021)

Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer
por: Cho, Beomyoung, et al.
Publicado: (2022)

Clinical trials update: endocrine and biological therapy combinations in the treatment of breast cancer
por: Leary, Alexandra F, et al.
Publicado: (2007)

Fulvestrant and the sequential endocrine cascade for advanced breast cancer
por: Johnston, S
Publicado: (2004)

Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review
por: Reinert, Tomás, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_057ro9ku09q5rcdi4ldlkna7be